Pura Vida Investments’s Vanda Pharmaceuticals VNDA Stock Holding History

Pura Vida Investments’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-67,500	Closed	-$564K	–	91
2016 Q1	$564K	Buy	+67,500	New	+$554K	0.26%	65
2015 Q4	–	Sell	-247,500	Closed	-$2.79M	–	90
2015 Q3	$2.79M	Sell	247,500 -60,000	-20%	-$734K	1.59%	25
2015 Q2	$3.76M	Buy	307,500 +227,117	+283%	+$2.45M	1.93%	18
2015 Q1	$748K	Buy	80,383 +30,383	+61%	+$343K	0.39%	51
2014 Q4	$716K	Buy	+50,000	New	+$592K	0.26%	64

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pura Vida Investments's VNDA Position: Q2 2016 in Review

Pura Vida Investments sold out of Vanda Pharmaceuticals (VNDA) in Q2 2016, closing a stake of 67,500 shares — an estimated $564K sold.

Pura Vida Investments first reported a position in VNDA in Q4 2014 and held it in 5 quarters. The position peaked at $3.76M in Q2 2015. 115 funds tracked by Wall St. Rank hold VNDA as of Q2 2016.

Pura Vida Investments reported no remaining Vanda Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Pura Vida Investments sold 67,500 Vanda Pharmaceuticals shares in Q2 2016, an estimated $564K.
Pura Vida Investments first reported a position in Vanda Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Pura Vida Investments's Vanda Pharmaceuticals position peaked at $3.76M in Q2 2015.
115 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2016.

Based on Pura Vida Investments's 13F filing for Q2 2016, filed 15 Aug 2016.